For the development of a CTL response, antigens have to escape from the endosomal compartment into the cytosolic and endoplasmic reticular space, where the cross-presentation occurs [3]. Micro- and nanoparticle-based vaccine delivery systems can function as antigen carriers. Their particulate nature has some inherent ability to facilitate

antigen cross-presentation [3], since they resemble pathogens particulate structure that looks like the biological situation. Particles Inhibitors,research,lifescience,medical per se are passively directed to the APCs and can increase the interaction between these cells and the antigen due to particles slow degradation [1]. Apart from the depot effect, particulate adjuvants can directly activate innate immunity in vivo [14]; that is, they work as immunoadjuvants. Thus, modification of these systems to directly target APCs may be Inhibitors,research,lifescience,medical a good approach for improving their efficacy. Therefore, micro- and nanoparticulated delivery systems can lead good opportunities in the development of synthetic peptide-based

Inhibitors,research,lifescience,medical vaccines (Figure 1). Figure 1 Schematic overview of the immune response developed after vaccination with micro- and nanoparticles entrapping antigenic peptides. When preparing micro- or nanodevices, there are some key formulation aspects such as chemical composition and manufacturing process, which affect the antigen loading capacity and release profile, product

stability, efficacy, and safety [15]. For instance, the difference in size between micro- and nanoparticles may change the immune response achieved. The smaller the particle, the greater the proportion of drug located on its surface. This can lead to a substantial Inhibitors,research,lifescience,medical loss of payload or to a lower maximal drug loading for smaller particles [16], which finally may affect to the adjuvant activity. Moreover, the preparation Inhibitors,research,lifescience,medical process of micro- and nanoparticles can lead to stability CB-839 datasheet problems due to the exposure to strong stress conditions (e.g., aqueous/organic interfaces, hydrophobic surfaces, and vigorous shaking) [17]. For this reason, peptide stability, once entrapped into the formulation, should be evaluated, since it is unlikely to develop a universal encapsulation approach appropriate to every peptide. For instance, in order to study the stability of the SPf66 peptide for encapsulated into PLGA MPs, Carcaboso et al. [18] analyzed peptide integrity by polyacrylamide gel electrophoresis and showed no bands indicating partial degradation or aggregation of the protein. Nowadays, there are no marketed vaccines composed of synthetic peptides. However, there are approved vaccines based on micro- and nanotechnologies. Alum is the most widely used adjuvant for human vaccines in the form of particulated aluminium salts (generally, Al(OH)3 and AlPO4) [19].